Respiratory Motion is more than halfway through an $8.8 million Series B funding round, along the way touting positive findings from a trial of its ExSpiron ventilation monitor.
Respiratory Motion is on a roll, landing nearly $6 million in new funding and unveiling positive results from a clinical study of its ExSpiron non-invasive respiratory monitor.
The Waltham, Mass.-based hopes to close the Series B round with $8.8 million, having raised $5.8 million so far from lead investor Easton Capital and other existing investors. The funds are slated to support sales and marketing efforts for the ExSpiron system, the company said.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1fbaoch
Cap comentari:
Publica un comentari a l'entrada